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Population-based disease registers identify and characterize all cases of disease, including those
that might otherwise be neglected. Prospective population-based registers in neurodegeneration
are necessary to provide comprehensive data on the whole phenotypic spectrum and can guide
planning of health services. With the exception of the rare disease amyotrophic lateral sclerosis,
few complete population-based registers exist for neurodegenerative conditions. Incomplete
ascertainment, limitations and uncertainty in diagnostic categorization, and failure to recognize
sources of bias reduce the accuracy and usefulness of many registers. Common biases include
population stratification, the use of prevalent rather than incident cases in earlier years, changes
in disease understanding and diagnostic criteria, and changing demographics over time. Future
registers are at risk of funding shortfalls and changes to privacy legislation. Notwithstanding,
as heterogeneities of clinical phenotype and disease pathogenesis are increasingly recognized
in the neurodegenerations, well-designed longitudinal population-based disease registers will
be an essential requirement to complete clinical understanding of neurodegenerative diseases.
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GLOSSARY
AD 5 Alzheimer disease; ALS 5 amyotrophic lateral sclerosis; EHR 5 electronic health record; FTD 5 frontotemporal
dementia; PD 5 Parkinson disease.
The extent of heterogeneity in clinical phenotype and disease pathogenesis is increasingly rec-
ognized in the neurodegenerations, and population-based disease registers can provide high-
quality longitudinal data that enable comparative analysis of demographics, phenotype, and
outcome across different geographic regions.
Registers differ from other types of patient-related data such as electronic health records
(EHRs), routine statistics held within national health services, and surveillance based on repre-
sentative samples (e.g., the US National Health and Nutrition Examination Survey). Register
data are actively collected (core data1,2), and require rigorous standardized management. By
contrast, EHRs are collected at the time of patient encounter and are coded based on the
diagnosis at that time. While such records can be useful as source datasets in the construction
of registers, EHRs alone are rarely sufficiently accurate or complete to enable the detailed
surveillance associated with disease registers, as exemplified recently by comparison of an
administrative database with a population-based register for amyotrophic lateral sclerosis
(ALS) in France.3
Restricted quality registers for neurodegeneration have been established in some regions, such
as SveDem, an Internet-based quality registry that includes patients from memory clinics and
primary care units with an estimated capture rate of 36%.4 Similarly, a French Dementia
Register comprises 84% of memory clinics.5 These registers are not designed to recruit within
the entire population, and while valuable in defining the characteristics of those enrolled, they
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are by definition limited by their design and
cannot provide an entire perspective of all
cases with dementia.
Most population-based registers require
a number of years of activity to ensure that
early biases are resolved. Once fully functional,
they can facilitate detailed analyses of disease
heterogeneity, risk, health planning, and mon-
itoring of disease burden in the population.6–14
The purpose of this review is to analyze the
methods underpinning existing population-
based registers for neurodegeneration, to
provide insights into hidden biases that can
confound analysis of register-based data,
and to suggest methods to minimize errors
of interpretation.
EXISTING POPULATION-BASED REGISTERS IN
NEURODEGENERATION Few true population-
based registers of adult neurodegenerative disease
currently exist. Examples of successful registers
include those developed for ALS6–8 and fronto-
temporal dementia (FTD).9–11 The European ALS
registers can be viewed as gold standards for rare
neurodegenerative diseases, as they have provided
important insights into disease pathogenesis, clin-
ical heterogeneity, and spatial distribution.6,12–14
Conversely, a relatively low number of true
population-based registers for commoner conditions
such as Parkinson disease (PD) and Alzheimer disease
(AD) have been established, primarily in Scandinavia,
the Netherlands, and some regions of the United
States.9,15,16 The Nebraska Parkinson’s Disease Reg-
ister17 has 98% ascertainment and uses capture-
recapture analysis,15,18,19 which combines information
from multiple ascertainment sources to estimate the
number of cases that are likely to have been missed.
Logistics of collection are aided through the support
of state law, and the register ascertains from multiple
sources with a verification process for all reported
cases.15,17 This register is feasible in part due to the
low population of Nebraska (1.8 million), which al-
lows identification of all cases in a relatively labor-
intensive manner. Given the high prevalence of PD
in most countries (329.3/100,000 in Nebraska15), the
costs of directly applying these methods in more pop-
ulous regions would be considerable.
As demonstrated by the Nebraska register, regis-
ters require active ascertainment from multiple sour-
ces to exclude possible coding errors, and to identify
those within the population who may not engage
with specialist services (figure). Exclusive reliance
on passive capture through existing records risks
ascertainment bias. For example, an approach for
PD in Thailand (population 67 million) using 3
independent administrative sources achieved only
66% case ascertainment.20
Registers from Scandinavia,21 Canada,22 the
United States,23 and Taiwan24 have ascertained cases
using administrative EHRs. As exemplified by a pre-
scription-based register for AD in Finland requiring
stringent proof of diagnosis, such an approach can
successfully exclude coding errors if administrative
records are a priori designed to ensure reliability in
ascertainment. However, use of EHRs that focus
exclusively on drug prescription may also introduce
other types of selection biases, as it is unlikely that all
patients with neurodegenerative disease will use
targeted medications.25 Even in countries with well-
developed social health systems such as Finland, addi-
tional sources of ascertainment are required.
In general, studies that have ascertained cases only
from specialist clinics, such as behavioral or old age
psychiatry clinics for AD, are also likely to be biased,26
as referral patterns can vary based on age, income
levels, and educational status (figure). There is evi-
dence that specialist clinics are likely to exclude very
early and very advanced cases,26–29 and those with
a very aggressive course, as exemplified by data from
the Irish ALS Register (table 1). Extrapolation from
these types of datasets is limited by selective partici-
pation and attrition, particularly in dementia studies.
As cohorts are more likely to be younger, interpreta-
tion of datasets from specialist memory clinics cannot
be generalizable to the entirety of people with demen-
tia, the majority of whom within the population are
over 85 years of age.30 Because of this, biomarkers and
prognostic indicators that are inferred from analysis of
cohorts cannot be applied to the community at large.
This high likelihood of a false-positive effect has been
shown for mild cognitive impairment.29
ALTERNATIVE APPROACHES TO POPULATION-
BASED REGISTERS: POPULATION-BASED
COHORT STUDIES Given the known logistical chal-
lenges associated with full ascertainment of patients
with common neurodegenerative disease, other meth-
ods based on complete follow-up of an entire or
a randomly selected population in a small area have
been used. All residents within a specific age range are
regularly screened for the disease and exposures of
interest, and are followed up regardless of the pres-
ence or absence of diagnosis. Examples of these types
of studies include the FraminghamHeart Study,31 the
Swedish National Study on Aging and Care,32 and
the Rotterdam Study in Holland. As exemplified by
the Rotterdam study,33–35 all residents within a spe-
cific region and age category (over 55) are invited to
participate in a longitudinal study of multiple health
outcomes. These types of studies repeatedly evaluate
the participating subject cohorts over many years, and
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statistical assessment of associations between risk
factors and disease incidence is determined. A major
strength is that members of the population are reg-
ularly examined, including those who have not fully
engaged with health services. New cases are identified
at each repeated screening/visit that occurs within the
target region. This differs from the traditional con-
cept of a disease register, as the parent study is usually
not restricted to a single diagnostic criterion for
inclusion, but instead typically includes a range of
diseases across specialties.33 However, by capturing
information about diverse diseases within and across
specialties, this method can be of great utility in
collecting a true population-based estimate of com-
mon but heterogeneous conditions such as dementia
or parkinsonism.33 It also has the advantage that it can
capture ongoing changes in diagnostic criteria and can
determine whether revised diagnoses predict out-
comes. Another advantage of this approach is that the
inclusion of healthy people within the cohort allows
the rigorous assessment of both premorbid exposures
and symptoms.33,35 This is valuable because the
pathogenesis of some forms of neurodegeneration
(e.g., dementia and PD) is known to be multifacto-
rial, and utilization of a design that continuously
samples and reassesses a population regardless of their
diagnosis can facilitate large longitudinal studies that
provide more accurate data pertaining to both clinical
phenotype and risk. This approach has a further
advantage of enabling recognition and evaluation of
clinical conditions (comorbidities) and other changes
that typically occur in elderly populations.
However, methods that depend on regular assess-
ment of specified populations also have important
limitations. They are not feasible for rare neurodegen-
erative conditions as it would be impossible to sample
a sufficiently large population to enable detection of
a large number of cases. Moreover, all cohorts are vul-
nerable to selective enrollment and attrition. For
example, cognitive impairment strongly predicts
study dropout,36,37 potentially leading to substantial
underestimates of dementia incidence. Extremely
fast-progressing cases may never be identified in
cohorts, because a patient may be diagnosed and
die during the interval between 2 assessment waves.
This can result in misleading estimates of disease
Figure Schematic overview of the care pathways undergone by patients with neurodegenerative diseases
Population-based registers must aim to reliably and consistently identify patients from all pathways, requiring government and
institutional support, sufficient funding and manpower, and local expertise. Social, demographic, and clinical selection biases
can influence the characteristics of patients following each pathway, and this can vary by disease and by health care system.
As a result, research studies recruiting from single pathways will inherit these biases. Functioning population-based registers
overcome these biases via inclusion of all pathways. Adapted from The Lancet (Brayne C, Davis D. Making Alzheimer’s and
dementia research fit for populations. Lancet 2012;380:1441–1443), © 2012, with permission from Elsevier.26
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prognosis, and introduces bias in the analysis of pre-
dictors of prognosis. In addition, although arguably
the best possible design for common diseases, large
health study cohorts remain at risk from drawing
from a narrow socially or geographically defined tar-
get population. A restricted definition of the target
population undermines one of the key purposes of
registers and extreme residential segregation by social
factors, as is common in the United States,38 can
exacerbate this challenge. Solutions to this problem
could be to link data from multiple sites, although
this would entail substantial challenges in both logis-
tics and funding, or to combine data from different
cohort studies,39 although this would not resolve the
inherent biases within each individual cohort study.
ESSENTIAL CONSIDERATIONS FOR NEW
REGISTERS Core content. Population-based regis-
ters in neurodegenerative diseases recognize the
importance of defining in advance and collecting core
content for all cases that fulfil the diagnostic criteria
for ascertainment.1,2 Standardization permits accurate
comparative analyses of different geographic
populations and data pooling to enhance statistical
power. The NIH/National Institute of Neurological
Disorders and Stroke in the United States has recently
defined detailed common data elements for a range of
neurologic diseases,1 and the European Platform for
Rare Disease Registries in Europe has proposed amore
general set of common data elements for use in rare
disease registries.40 A requirement for excessive detail
increases participant burden and the likelihood of
missing data, and for this reason extensive clinical
data (such as would be required for care pathways)
are not suited to registers. Such data are best gener-
ated as additional nested studies associated with but
not part of the core functioning of a prospective lon-
gitudinal register (table 2).
Recognizing ascertainment bias. The principal advan-
tage of the population-based register is the minimiza-
tion of sources of bias (table 3). Although elimination
of all forms of ascertainment bias is not possible in the
design and establishment of any new register, a recog-
nition of the likely sources of bias is important. Factors
that can assist the reduction of ascertainment biases
Table 1 Characteristics of a population-based cohort of Irish patients with amyotrophic lateral sclerosis (ALS)




only (n 5 814)
Clinic nonattenders
only (n 5 468)
p Value (clinic attenders
vs nonattenders)
Sex, n (%)
Male 723 (56.4) 458 (56.3) 265 (56.5)
Female 559 (43.6) 356 (43.7) 203 (43.4) 0.907
Mean (SD) age at onset, y 64.6 (11.9) 62.3 (11.7) 68.4 (11.5) ,0.0001a,b
Diagnostic delay, wk, n (%)
<31 380 (33.8) 232 (31.9) 148 (37.4)
31–55 371 (33.0) 240 (33.0) 131 (33.1)
>55 372 (33.2) 255 (35.1) 117 (29.6) 0.098
Site of onset, n (%)
Limb 743 (58.4) 516 (63.8) 227 (48.7)
Bulbar 465 (36.5) 257 (31.8) 208 (44.6)
Limb and bulbar 65 (5.1) 34 (4.2) 31 (6.7) ,0.001b
El Escorial, n (%)
Definite 709 (56.2) 436 (54.1) 273 (59.7)
Probable 386 (30.6) 255 (31.7) 131 (28.7)
Possible 153 (12.1) 107 (13.3) 46 (10.1)
Suspected 14 (1.1) 7 (0.9) 7 (1.5) 0.101
Median unadjusted survival
(95% CI) from diagnosis
1.27 (1.20–1.36) 1.51 (1.40–1.62) 0.93 (0.80–1.05) ,0.0001b,c
Abbreviation: CI 5 confidence interval.
The figures are from a population sample of patients with ALS in Ireland; those who do not attend clinic are older, have
poorer prognosis, and are more likely to have bulbar-onset ALS compared to those who attend clinic. This illustrates the
importance of population-based case ascertainment for the study of neurodegenerative diseases.
aStudent t test. Others tests are Fisher exact test.
bSignificant.
cMantel-Haenszel rate ratio 5 0.657 for clinic attenders vs nonattenders.
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include clearly defined and rigorously applied geo-
graphic boundaries,7,41 stability of the population
within a designated capture region, and recognition of
migration patterns. Prospective design42 and longitu-
dinal follow-up with the intention of complete ascer-
tainment of all affected individuals can reduce known
bias, as does a stable population structure with limited
mobility, which minimizes the risk of bias associated
with loss of follow-up.
As noted, no single data source is likely to identify
all cases in population-based registers, and multiple
sources of identification can improve reliability of
ascertainment and ensure that the range and extent
of disease heterogeneity is represented.7,42 The use
of capture recapture analysis6,15,18,19 based on 2 or
more independent source datasets permits evaluation
of the degree of completeness of ascertainment, so
that the population burden of cases can be estimated
even if no source is complete.
Effective case identification strategies include re-
ferrals through networks of clinical professionals,
death certification, and face-to-face or telephone-
based interviews. Pitfalls that introduce bias include
the use of single sources of ascertainment. These
include collection of patients exclusively through spe-
cialist clinics as noted (tables 1 and 3), self-reporting
of patients through online portals, or exclusive reli-
ance on codes from billing data, which are subject to
selection bias and diagnostic error.3,43,44 Death certi-
fication may also overestimate or underestimate dis-
ease incidence because of inaccurate recording and
coding.45,46
Bias of diagnostic uncertainty. Population-based regis-
ters require a high level of vigilance to exclude errone-
ous diagnoses and mimic syndromes in both rare and
common diseases.47–49
Diagnostic certainty is problematic for both rare
and common neurodegenerative diseases for different
reasons. Rare diseases may not be recognized outside
of specialist centers. Conversely, certainty of diagnosis
of common diseases (e.g., dementias) can be limited
by the absence of strict diagnostic criteria, and logis-
tics surrounding the acquisition of sufficiently
detailed clinical information to ensure clarity for
inclusion purposes. This is a particular problem in
the ascertainment of cognitive impairment that pres-
ages dementia. While memory clinics advocate regu-
lar screening, such an initiative is not practical within
a population-based setting, and also risks the genera-
tion of false-positive diagnoses.28,29
Table 3 Common sources of bias and their resolution
Bias source Bias implication Resolution
Ascertainment from sources
other than population
Incomplete data, very young, very old, and
very severe and very mild cases likely to be
excluded; economically disadvantaged/
minorities excluded
Multiple sources with capture recapture
Prevalent cases only or mixed
incident and prevalent cases
recruited
Milder cases, incomplete clinical phenotypes,
and longer natural history
Longitudinal incident-based inclusion
Diagnostic certainty Misdiagnoses and mimic syndromes included Quality control, review of source
documentation, autopsy reports; excluding the
most recent 1–2 years of data capture (or
longer if the condition has long lag from initial
diagnosis to inclusion on the register)
Startup bias Mixture of incident and prevalent cases
included; clinical phenotype and natural
history data skewed in favor of milder cases
with better survival
Recognition, employment of careful statistical
analyses of data collected in the first 3–5
years to account for startup bias
Information creep Subtle changes in inclusion criteria;
differences in clinical phenotype between
historical cases and those recently enrolled
Awareness, rigorous use of core data
elements; addition of new fields with
additional data; correction for missing data
from earlier cohorts
Period and cohort effects Reasons for true differences between
different cohorts misattributed
Awareness; mathematical correction where
possible; rigorous attention and correction for
missing data
Table 2 Essential design aspects for
population-based registers
Register variables should be selected carefully and a core
content paradigm should be agreed upon in advance.
Core content should include clearly defined case definitions
and these should be applied within a framework of
specifically stated inclusion and exclusion criteria.
Capture methodology should be clearly defined in advance.
Case identification pathways should be agreed upon in
advance and should include multiple sources for
identification of incident cases.
Core content should facilitate international collaborative
efforts or national merger of data in large countries using
multiple registers to cover different regions is advisable for
rare diseases.
Identification of data manager and data controller and clear
definition of governance structures is necessary.
Compliance with local data protection legislation and ethical
constraints is required.
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Some neurodegenerations have low clinicopatho-
logic correlation,50–52 and a recent meta-analysis on
diagnosis of PD showed that 1 out of 5 diagnoses of
is wrong.53 The low clinicopathologic concordance is
not intrinsic to register data, but reflects real
ambiguity and controversy in the clinical diagnoses,
the frequent overlap between different types of neuro-
degeneration (e.g., AD, vascular dementia, and Lewy
body dementia50), and imperfect correspondence
between clinical symptoms and neuropathologic bases
of disease in some instances.53 Moreover, diagnoses in
neurodegeneration may shift with changing symptoms
during the course of the disease, and some differential
diagnoses (e.g., corticobasal degeneration vs progres-
sive supranuclear palsy) can only be made after specific
symptoms develop, or even at the time of autopsy.52
These limitations, although difficult to address at the
time of ascertainment, should be anticipated in the
design of population-based neurodegenerative disease
registers by incorporating ongoing collection of clini-
cal data at regular intervals and by regular quality
control assessment by review of source documents,
correlation with death certificates, and where possible,
autopsy reports.
Bias of including mixed incident and prevalent cohorts.
Inclusion of both prevalent and incident cases in pro-
spective disease registers introduces bias. Collection of
incident cases generally facilitates the characterization
of phenotype throughout the disease course, includ-
ing variability in progression when ascertained longi-
tudinally over an extended period of time.42,54
Conversely, inclusion of prevalent cases can bias char-
acterization of the natural history of disease because
prevalent cases will on average overrepresent more
slowly progressing and less severe cases.54,55 This bias
is most likely to occur when patients are ascertained
from clinic cohorts, which generally cater for a larger
proportion of prevalent rather than incident
cases.6,26,54–57 Clinical trial cohorts such as the
Pooled Resource Open-Access ALS Clinical Trials
(PRO-ACT) database are also subject to this type of
bias.58 Population-based registers of incident cases
that have been in operation for long periods of time
catalogue all incident and prevalent cases and effec-
tively eliminate this source of bias.
Startup bias. Data captured in the early years of a reg-
ister are unlikely to be of the same quality as subse-
quently captured data, as there is generally a bias
towards enrollment of prevalent rather than incident
cases. Also, most registers miss some cases in the early
years. Such issues are inevitable in the initiation years
of any disease register regardless of how well the
methodology of capture of cases is planned. This cre-
ates a substantial bias that is rarely recognized, but
that must be accounted for in later analyses. As the
register develops, the multisource case ascertainment
mechanism becomes more streamlined, data are col-
lected prospectively, and the target population be-
comes aware of the register, reducing rates of
missing values. Therefore, startup bias must be con-
sidered in interrogating registers of recent origin,
especially when evaluating time to event outcomes
(e.g., with survival analysis).59 This bias also applies
to analysis of data from recent case ascertainment in
longstanding registers, as there is usually a time lag
between case ascertainment and quality control meth-
ods that ensure diagnostic accuracy. To minimize
these types of bias, analyses should be conducted by
excluding data acquired at the beginning of the reg-
ister, and within a specified period (often the previous
year) of recent case ascertainment.
Changes of disease definition. The changing under-
standing of different clinical diagnoses and their inter-
relationships presents challenges for registers. For
example, there is now a recognition that the clinical
condition commonly classified as dementia of the
Alzheimer type is heterogeneous, with contributing
vascular and inflammatory factors, and the value of
detailed phenotype characterization is accordingly
increasingly recognized. Similarly, ALS was tradition-
ally considered to be a neurodegenerative disorder
confined to the motor system. However, it is now rec-
ognized that cognitive and behavioral changes are
intrinsic features of the condition.37,60,e1 The overlap
between ALS and FTD has been further recognized
following the discovery of the C9orf72 hexanucleo-
tide repeat expansion.e2,e3 Inclusion of cognitive and
genetic status is now recognized as an important core
element of ALS registers, necessitating adjustment of
the existing core datasets, and effectively leading to
a large volume of missing data for patients captured
by ALS registers in the 1990s and early 2000s.
For these reasons, comparative analyses of register
data collected over long periods of time can be prob-
lematic, both from the perspective of missing data
and in relation to the effect that this new information
has on the process of case ascertainment and inferen-
ces regarding risk. Moreover, although successful
population-based registers may boast complete ascer-
tainment, it is likely that the increased recognition of
both comorbidities and subphenotypes can lead
to subtle shifts in the types of patients who are
included.e4–e6
As is the case with diagnostic certainty, there is no
mechanism to eliminate this type of bias. However, it
is important to be aware that it exists, and that com-
parative analyses of data across time intervals will be
subject to the bias of information creep.
In addition to the bias of evolving information and
subtle changes in diagnostic categorizations, period
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and cohort effects should also be recognized during
comparative analyses across different time periods of
an individual register, and across registers from differ-
ent regions and of different durations. It cannot be
assumed that populations ascertained by registers at
different time intervals are the same, and these effects
should be taken into account when performing com-
parative analyses. For these reasons, the use of histor-
ical controls in the evaluation of interventions
introduces a bias that cannot be evaluated.
CHALLENGES IN MANAGING LONGITUDINAL
REGISTERS Logistics and infrastructure. Registers are
extremely vulnerable to interruptions in funding. Dis-
ease registers are cost- and labor-intensive, and (unlike
EHRs) require active management to ensure unifor-
mity of ascertainment and ongoing quality control.
The costs of establishing and maintaining a register
will depend on (1) the size of the study population,
(2) the type of disease (e.g., common or rare), and (3)
the nature of the health service within which the
register operates. In all cases, sustainable funding is
challenging in the absence of a specific government/
funding agency policy commitment, such as has
occurred in the United States with the inception of
the US ALS register,e7,e8 and in Denmark, where the is
a strong historical tradition of supporting high-quality
longitudinal registers with interlocking datasets that
are open to interrogation.e9 With these exceptions,
disease registers continue to be viewed by many
funding agencies as infrastructural resources rather
than essential research instruments, and are excluded
from funding as they do not of themselves generate
research outputs. Indeed, in a recent survey of
European rare disease registers, 23% of 202 registers
were established with no specific source of funding.e10
Unstable funding streams devalue the original in-
vestments in establishing a register because the data
become more valid, comprehensive, and reliable over
years as the register matures.
Ethics and data protection legislation. The sustainability
of registers in the longer term is challenged by ongo-
ing limitations on the types of data that disease regis-
ters are likely to be permitted to record. Data
protection legislation has been strengthened within
the last 20 years, and inclusion of data regarding liv-
ing patients without their expressed informed consent
in the absence of specific legislation is now in breach
of data protection laws in Europe. This has the poten-
tial to introduce bias.
These problems could be addressed by legislation
providing a derogation for population-based registers
from the full strictures of data protection legislation
as in the case of the Nebraska Parkinson’s Disease
Register,15 while maintaining strict control in the types
of access permitted. This requires an understanding
and recognition by the public of the important poten-
tial societal benefits of population-based epidemiologic
research, and in particular the potential public health
benefit of identifying and communicating de-
identified data regarding regional variations in disease
incidence, prevalence, and survival. This benefit,
which is implicit in the case of notifiable infectious
and communicable diseases, is juxtaposed with the
right to privacy of the individual. While some coun-
tries created registers that are now core research tools
(e.g., the US ALS registry, the Danish registers, and
cancer registers inmany countries), there remains a lim-
ited recognition within Europe of the public health
and societal benefits of such an approach for most
noncancer and noncommunicable disease from the
dual perspectives of research and public health/policy.
The issues of privacy and data protection must be
clearly addressed in registers and data should be codi-
fied to exclude personal identification. Clearly enunci-
ated protocols should be in place to determine who can
access the data, and the circumstances under which
this access is permitted. Nevertheless, the goals of fos-
tering access by qualified researchers and preventing re-
identification are sometimes in competition. Recent
efforts to enhance data-sharing throughout the health
research community have fostered innovations in data
security, and investment in adopting these protocols
and updating as new technologies become available is
important to ensure the confidentiality of participants
while maximizing research applications.
DISCUSSION Acknowledgment, recognition, and
rectification of the inherent biases within population-
based datasets is necessary for accurate demographic
and deep phenotypic characterization of neurodegen-
erative diseases. However, some biases within registers
can never be fully avoided. Notwithstanding, appro-
priate interrogation of register data can build our
understanding of clinical and biological heterogeneity
of neurodegenerative diseases within and across dif-
ferent populations. Well-designed population-based
registers are essential to the provision of accurate
epidemiologic and phenotypic characterization that
will drive understanding of the heterogeneous disease
mechanisms underpinning rare and common neuro-
degenerative diseases.
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